#Liver-Safety

2 stories

Regulatory May 4, 2026 · View digest

Foundayo Liver Failure FAERS Report Surfaces; Lilly Stock Falls 3% Premarket Before Recovering

An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.

Industry May 4, 2026 · View digest

RBC Capital Defends LLY: Foundayo Single Liver Case is 'Baseline Noise, Not a Mechanistic Safety Signal'

RBC Capital reiterated its Outperform rating on Eli Lilly May 4 with the framing 'baseline noise, not a mechanistic safety signal,' and put the single Foundayo case in context against the broader GLP-1 class hepatic failure tally: Mounjaro 30 cases, Zepbound 2, Ozempic 33, Wegovy 15. Other Street analysts followed similar reasoning. The defense rests on the 11,000-patient clinical program and the absence of any DILI signal across two years of follow-up. The framing matters because the launch trajectory for Foundayo had already been challenged by IQVIA tracker data showing the Wegovy pill running roughly 20× ahead in retail prescriptions; a sustained safety overhang would compound the commercial pressure.